DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 9, 2010, Pages 659-667

  Zhang, Donghong ^a   Ai, Ding ^b   Tanaka, Hiromasa ^c   Hammock, Bruce D ^c   Zhu, Yi ^a,b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatocyte; Methylation; SEH; SP 1

Indexed keywords

DNA; EPOXIDE HYDROLASE; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN;

ARTICLE; BINDING SITE; BIOINFORMATICS; CARCINOGENESIS; CARCINOMA; CELL PROLIFERATION; CELL STRAIN HEPG2; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; EMBRYO; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY CELL; MOLECULAR MECHANICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

BASE SEQUENCE; CACO-2 CELLS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA METHYLATION; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEK293 CELLS; HEP G2 CELLS; HEPATOCYTES; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; SOLUBILITY; SP1 TRANSCRIPTION FACTOR;

EID: 78149415042     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.09.006     Document Type: Article

References (40)

1. Newman J.W., Morisseau C., Harris T.R., Hammock B.D. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl Acad. Sci. USA 2003, 100:1558-1563.
2. Tran K.L., Aronov P.A., Tanaka H., Newman J.W., Hammock B.D., Morisseau C. Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. Biochemistry-Us 2005, 44:12179-12187.
3. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., Kroetz D.L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 2000, 87:992-998.
4. Enayetallah A.E., French R.A., Thibodeau M.S., Grant D.F. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J. Histochem. Cytochem. 2004, 52:447-454.
5. Newman J.W., Morisseau C., Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 2005, 44:1-51.
6. Capdevila J.H., Falck J.R., Harris R.C. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res. 2000, 41:163-181.
7. Spiecker M., Liao J.K. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch. Biochem. Biophys. 2005, 433:413-420.
8. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002, 39:690-694.
9. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl Acad. Sci. USA 2005, 102:9772-9777.
10. Jung O., Brandes R.P., Kim I.H., Schweda F., Schmidt R., Hammock B.D., Busse R., Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45:759-765.
11. Yang M.D., Wu C.C., Chiou S.H., Chiu C.F., Lin T.Y., Chiang I.P., Chow K.C. Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma. Oncol. Rep. 2003, 10:271-276.
12. Enayetallah A.E., French R.A., Grant D.F. Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J. Mol. Histol. 2006, 37:133-141.
13. GOLDSTEIN M.N., SLOTNICK I.J., JOURNEY L.J. In vitro studies with HeLa cell line sensitive and resistant to actinomycin D. Ann. NY Acad. Sci. 1960, 89:474-483.
14. Leibovitz A., Stinson J.C., McCombs W.R., McCoy C.E., Mazur K.C., Mabry N.D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976, 36:4562-4569.
15. Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl Cancer Inst. 1977, 58:209-214.
16. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 1978, 21:274-281.
17. Aden D.P., Fogel A., Plotkin S., Damjanov I., Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979, 282:615-616.
18. Pear W.S., Nolan G.P., Scott M.L., Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl Acad. Sci. USA 1993, 90:8392-8396.
19. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
20. Jiang J.G., Chen C.L., Card J.W., Yang S., Chen J.X., Fu X.N., Ning Y.G., Xiao X., Zeldin D.C., Wang D.W. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 2005, 65:4707-4715.
21. Michaelis U.R., Fisslthaler B., Medhora M., Harder D., Fleming I., Busse R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J. 2003, 17:770-772.
22. Burke Y.D., Stark M.J., Roach S.L., Sen S.E., Crowell P.L. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 1997, 32:151-156.
23. Edwards P.A., Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 1999, 68:157-185.
24. Wang Z., Chen H.T., Roa W., Finlay W. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J. Pharm. Pharm. Sci. 2003, 6:95-100.
25. Tanaka H., Kamita S.G., Wolf N.M., Harris T.R., Wu Z., Morisseau C., Hammock B.D. Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2. Biochim. Biophys. Acta 2008, 1779:17-27.
26. Zhu Y., Lin J.H., Liao H.L., Jr Friedli O., Verna L., Marten N.W., Straus D.S., Stemerman M.B. LDL induces transcription factor activator protein-1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 1998, 18:473-480.
27. Ai D., Pang W., Li N., Xu M., Jones P.D., Yang J., Zhang Y., Chiamvimonvat N., Shyy J.Y., Hammock B.D., Zhu Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc. Natl Acad. Sci. USA 2009, 106:564-569.
28. Ai D., Fu Y., Guo D., Tanaka H., Wang N., Tang C., Hammock B.D., Shyy J.Y., Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA 2007, 104:9018-9023.
29. Boyd K.E., Farnham P.J. Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol. Cell. Biol. 1997, 17:2529-2537.
30. Moody T.W., Mantey S.A., Pradhan T.K., Schumann M., Nakagawa T., Martinez A., Fuselier J., Coy D.H., Jensen R.T. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J. Biol. Chem. 2004, 279:23580-23589.
31. Clark S.J., Harrison J., Molloy P.L. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 1997, 195:67-71.
32. Capdevila J.H., Nakagawa K., Holla V. The CYP P450 arachidonate monooxygenases: enzymatic relays for the control of kidney function and blood pressure. Adv. Exp. Med. Biol. 2003, 525:39-46.
33. Smale S.T. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Biochim. Biophys. Acta 1997, 1351:73-88.
34. Brandeis M., Frank D., Keshet I., Siegfried Z., Mendelsohn M., Nemes A., Temper V., Razin A., Cedar H. Sp1 elements protect a CpG island from de novo methylation. Nature 1994, 371:435-438.
35. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
36. Cao Y.X., Jean J.C., Williams M.C. Cytosine methylation of an Sp1 site contributes to organ-specific and cell-specific regulation of expression of the lung epithelial gene t1alpha. Biochem. J. 2000, 350(Pt 3):883-890.
37. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
38. Zhu W.G., Srinivasan K., Dai Z., Duan W., Druhan L.J., Ding H., Yee L., Villalona-Calero M.A., Plass C., Otterson G.A. Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol. Cell. Biol. 2003, 23:4056-4065.
39. Comb M., Goodman H.M. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res. 1990, 18:3975-3982.
40. Enayetallah A.E., Grant D.F. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. Biochem. Biophys. Res. Commun. 2006, 341:254-260.